OncoMatch/Clinical Trials/NCT03136146

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Is NCT03136146 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for recurrent acute lymphoblastic leukemia.

Phase 2RecruitingM.D. Anderson Cancer CenterNCT03136146Data as of May 2026

Treatment: Bortezomib · Clofarabine · Cyclophosphamide · Dexamethasone · Etoposide · Ofatumumab · Pegfilgrastim · Rituximab · Vincristine Sulfate Liposome — This phase II trial studies the side effects and how well combination chemotherapy works in treating patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt lymphoma/leukemia, or double-hit lymphoma/leukemia that has come back or does not respond to treatment. Drugs used in chemotherapy, such as clofarabine, etoposide, cyclophosphamide, vincristine sulfate liposome, dexamethasone and bortezomib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Lymphoblastic Leukemia

Non-Hodgkin Lymphoma

Acute Myeloid Leukemia

Biomarker criteria

Allowed: BCR Philadelphia positive

Philadelphia positive acute lymphoblastic leukemia, Burkitt leukemia/lymphoma or "double-hit" leukemia/lymphoma

Allowed: MYC rearrangement

double-hit lymphoma/leukemia

Allowed: BCL2 rearrangement

double-hit lymphoma/leukemia

Allowed: BCL6 rearrangement

double-hit lymphoma/leukemia

Performance status

ECOG 0–3(Limited self-care)

Lab requirements

Kidney function

Estimated creatinine clearance or GFR >= 50 mL/min

Liver function

Serum bilirubin <= 1.5 mg/dL; SGPT <= 3 x ULN, with exception for Gilbert's syndrome

Serum bilirubin <= 1.5 mg/dL; Serum glutamate pyruvate transaminase (SGPT) <= 3 x upper limit normal (ULN), with exception for Gilbert's syndrome; Estimated creatinine clearance or GFR (glomerular filtration rate) >= 50 mL/min

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

M D Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify